NCT03121716View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

July 28, 2020

Study Completion Date

July 31, 2020

Conditions

Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL

SHR-1210

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

DRUG

Gemcitabine

gemcitabine

DRUG

cis-platinum

Trial Locations (1)

Unknown

Jiangsu Hengrui, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03121716 - A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects | Biotech Hunter | Biotech Hunter